EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Preclinical Evaluation of an Integrin α v β 6 -Targeted Photodynamic Therapy

Hua Zhang iD, Tanushree Ganguly iD, Rebecca Harris, Ryan A Davis, Sven H Hausner, Luciana Kovacs, Julie L Sutcliffe iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Hua Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of California, Davis, California 95616, United States. Hauptthemen laut MEDLINE: Photochemotherapy, Photosensitizing Agents, Integrins, Antigens, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, Lustgarten Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Photodynamic therapy (PDT) is a minimally invasive treatment in which an external light source activates an injected photosensitizer (PS) to generate reactive oxygen species, causing localized cell death. Although the first PDT received FDA approval in 1995, clinical adoption has been limited, in part due to the limited tumor selectivity of PSs. The goal of this study was to develop a PS with improved tumor selectivity by incorporating a targeting peptide that selectively binds to the integrin αvβ6. The integrin αvβ6 is an epithelial-specific cell-surface receptor that is overexpressed in several cancer types, with expression level often linked to poor overall survival. The integrin αvβ6 targeting peptide (ABM-5G) was conjugated onto a water-soluble PS (IRDye700DX, IR700) in solution phase, and the resulting PS-αvβ6-targeted-peptide conjugate (IR700-ABM-5G, 1) demonstrated excellent photochemical and photophysical properties, including high extinction coefficient and singlet oxygen productivity similar to the nontargeted PS (free IR700). In vitro, 1 showed αvβ6-selective binding to and internalization into DX3puroβ6 (αvβ6+) cells vs DX3puro (αvβ6-) cells, and αvβ6-selective phototoxicity with EC50s of 1.6 nM for DX3puroβ6 cells and ≥ 250 nM for DX3puro cells. In mice bearing paired DX3puroβ6 (αvβ6+) and DX3puro (αvβ6-) tumor xenografts, the fluorescence intensity of 1 in DX3puroβ6 (αvβ6+) tumors was 2.5- to 7-fold higher than that of the other tissues (including DX3puro (αvβ6-) tumors, p < 0.0001), except for the kidneys and stomach. A single treatment of 1 (1.4 nmol per mouse) combined with near-infrared light exposure significantly suppressed the growth of DX3puroβ6 (αvβ6+) tumors (198 ± 112 mm3 vs 714 ± 251 mm3 for saline control, p < 0.0001, on day 37 post treatment). In summary, PDT treatment with 1 demonstrated αvβ6-selective therapeutic efficacy both in vitro and in vivo and is a promising targeted therapy for the treatment of a range of αvβ6-expressing cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhotochemotherapyPhotosensitizing AgentsIntegrinsAntigens, NeoplasmPeptidesAnimalsHumansMiceCell Line, TumorFemale

Substanzen

integrin alphavbeta6Photosensitizing AgentsIntegrinsAntigens, NeoplasmPeptides

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of California, Davis, California 95616, United States.
  • Department of Internal Medicine, Division of Hematology & Oncology, University of California, Davis, California 95817, United States.
  • Center for Molecular and Genomic Imaging, University of California, Davis, California 95616, United States.

ORCID-Profile: Hua Zhang, Tanushree Ganguly, Julie L Sutcliffe

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • Lustgarten Foundation

Zitieren

APA

Zhang, H., Ganguly, T., Harris, R., Davis, R. A., Hausner, S. H., Kovacs, L., & Sutcliffe, J. L. (2025). Preclinical Evaluation of an Integrin α v β 6 -Targeted Photodynamic Therapy. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00202

Vancouver

Zhang H, Ganguly T, Harris R, Davis RA, Hausner SH, Kovacs L, et al. Preclinical Evaluation of an Integrin α v β 6 -Targeted Photodynamic Therapy. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00202

BibTeX
@article{Zhang2025,
  author = {Zhang, Hua and Ganguly, Tanushree and Harris, Rebecca and Davis, Ryan A and Hausner, Sven H and Kovacs, Luciana and Sutcliffe, Julie L},
  title = {Preclinical Evaluation of an Integrin α v β 6 -Targeted Photodynamic Therapy},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00202}
}
Kostenlos starten →